Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Label, Non Controlled, Non Randomized, Interventional Study to Evaluate the Response Rate After Induction Therapy With DocEtaxel and CIsplatin in Unresectable Locally Advanced Squamous Cell Carcinoma of heaD and nEck

NCT02061631 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT02061631
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02061631 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Label, Non Controlled, Non Randomized, Interventional Study to Evaluate the Response Rate After Induction Therapy With DocEtaxel and CIsplatin in Unresectable Locally Advanced Squamous Cell Carcinoma of heaD and nEck
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2014
Completion date
October 31, 2015
Enrollment
35 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

squamous cell carcinoma of head and neck